UNSPSC 51201829: Tetramisole hydrochloride

This classification denotes a chemo immunostimulant adjuvant C11H12N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0NDK265MCV, chemically known as (+/-)-2,3,5,6-tetrahydro-6-phenylimidazo(2,1-b)thiazole monohydrochloride, but more generally known as tetramisole hydrochloride, which bears US NIH Compound Identifier 68628. Most nations, for tariff and trade purposes, schedule tetramisole hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, TETRAMISOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

SMILES: C1CCC(CC1)C2CN3CCSC3=N2.CL.

UNSPSC 51201829 Tetramisole hydrochloride is a Commodity code nominally identifying a specific pharmaceutical compound, but the sole recent state and local procurement activity posted under it involves yellow fever vaccine procurement rather than tetramisole itself. The Mississippi State Department of Health posted a notice of proposed sole source purchase on July 13, 2026, for yellow fever vaccine from Sanofi Pasteur, Inc., with objections due August 3, 2026. The code shows minimal recent activity, and the single opportunity on record does not match the code's stated pharmaceutical name, indicating either a tagging misalignment or very limited use of this code for state and local procurement.

The Mississippi State Department of Health is the only issuing body represented in the recent record. The solicitation is a sole source notice rather than a competitive RFP, RFQ, IFB, or ITB; the department will conduct a competitive process only if substantiated objections to the sole source designation are received and upheld by the Public Procurement Review Board. The notice does not specify quantity, contract term, estimated value, or pricing. Geographic activity is limited to Mississippi based on the available record.